Global Elrantamab Market Growth 2026-2032
The global Elrantamab market size is predicted to grow from US$ 297 million in 2025 to US$ 1143 million in 2032; it is expected to grow at a CAGR of 13.4% from 2026 to 2032.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000??52000 vials.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.
In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson?s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.
As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company?s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.
LP Information, Inc. (LPI) ' newest research report, the ?Elrantamab Industry Forecast? looks at past sales and reviews total world Elrantamab sales in 2025, providing a comprehensive analysis by region and market sector of projected Elrantamab sales for 2026 through 2032. With Elrantamab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Elrantamab industry.
This Insight Report provides a comprehensive analysis of the global Elrantamab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Elrantamab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Elrantamab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Elrantamab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Elrantamab.
This report presents a comprehensive overview, market shares, and growth opportunities of Elrantamab market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Elrantamab market?
What factors are driving Elrantamab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Elrantamab market opportunities vary by end market size?
How does Elrantamab break out by Type, by Application?
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000??52000 vials.
Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.
In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson?s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.
As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company?s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.
LP Information, Inc. (LPI) ' newest research report, the ?Elrantamab Industry Forecast? looks at past sales and reviews total world Elrantamab sales in 2025, providing a comprehensive analysis by region and market sector of projected Elrantamab sales for 2026 through 2032. With Elrantamab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Elrantamab industry.
This Insight Report provides a comprehensive analysis of the global Elrantamab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Elrantamab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Elrantamab market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Elrantamab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Elrantamab.
This report presents a comprehensive overview, market shares, and growth opportunities of Elrantamab market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 44 mg / 1.1 mL
- 76 mg / 1.9 mL
- Subcutaneous Injection Solution
- Lyophilized Powder for Injection
- Hospital
- Retail
- Online
- Monoclonal Antibody
- Polyclonal Antibody
- Bispecific Antibody
- Monotherapy for Relapsed or Refractory Multiple Myeloma
- Combination Therapy with Immunomodulators and Proteasome Inhibitors
- Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
- Otherts
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
What is the 10-year outlook for the global Elrantamab market?
What factors are driving Elrantamab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Elrantamab market opportunities vary by end market size?
How does Elrantamab break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Elrantamab Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Elrantamab by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Elrantamab by Country/Region, 2021, 2025 & 2032
2.2 Elrantamab Segment by Type
2.2.1 44 mg / 1.1 mL
2.2.2 76 mg / 1.9 mL
2.2.3 Elrantamab Sales by Type
2.2.3.1 Global Elrantamab Sales Market Share by Type (2021-2026)
2.2.3.2 Global Elrantamab Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Elrantamab Sale Price by Type (2021-2026)
2.3 Elrantamab Segment by Dosage Form
2.3.1 Subcutaneous Injection Solution
2.3.2 Lyophilized Powder for Injection
2.3.3 Elrantamab Sales by Dosage Form
2.3.3.1 Global Elrantamab Sales Market Share by Dosage Form (2021-2026)
2.3.3.2 Global Elrantamab Revenue and Market Share by Dosage Form (2021-2026)
2.3.3.3 Global Elrantamab Sale Price by Dosage Form (2021-2026)
2.4 Elrantamab Segment by Sales Channels
2.4.1 Hospital
2.4.2 Retail
2.4.3 Online
2.4.4 Elrantamab Sales by Sales Channels
2.4.4.1 Global Elrantamab Sales Market Share by Sales Channels (2021-2026)
2.4.4.2 Global Elrantamab Revenue and Market Share by Sales Channels (2021-2026)
2.4.4.3 Global Elrantamab Sale Price by Sales Channels (2021-2026)
2.5 Elrantamab Segment by Antibody Type
2.5.1 Monoclonal Antibody
2.5.2 Polyclonal Antibody
2.5.3 Bispecific Antibody
2.5.4 Elrantamab Sales by Antibody Type
2.5.4.1 Global Elrantamab Sales Market Share by Antibody Type (2021-2026)
2.5.4.2 Global Elrantamab Revenue and Market Share by Antibody Type (2021-2026)
2.5.4.3 Global Elrantamab Sale Price by Antibody Type (2021-2026)
2.6 Elrantamab Segment by Application
2.6.1 Monotherapy for Relapsed or Refractory Multiple Myeloma
2.6.2 Combination Therapy with Immunomodulators and Proteasome Inhibitors
2.6.3 Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
2.6.4 Otherts
2.6.5 Elrantamab Sales by Application
2.6.5.1 Global Elrantamab Sale Market Share by Application (2021-2026)
2.6.5.2 Global Elrantamab Revenue and Market Share by Application (2021-2026)
2.6.5.3 Global Elrantamab Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Elrantamab Breakdown Data by Company
3.1.1 Global Elrantamab Annual Sales by Company (2021-2026)
3.1.2 Global Elrantamab Sales Market Share by Company (2021-2026)
3.2 Global Elrantamab Annual Revenue by Company (2021-2026)
3.2.1 Global Elrantamab Revenue by Company (2021-2026)
3.2.2 Global Elrantamab Revenue Market Share by Company (2021-2026)
3.3 Global Elrantamab Sale Price by Company
3.4 Key Manufacturers Elrantamab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Elrantamab Product Location Distribution
3.4.2 Players Elrantamab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ELRANTAMAB BY GEOGRAPHIC REGION
4.1 World Historic Elrantamab Market Size by Geographic Region (2021-2026)
4.1.1 Global Elrantamab Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Elrantamab Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Elrantamab Market Size by Country/Region (2021-2026)
4.2.1 Global Elrantamab Annual Sales by Country/Region (2021-2026)
4.2.2 Global Elrantamab Annual Revenue by Country/Region (2021-2026)
4.3 Americas Elrantamab Sales Growth
4.4 APAC Elrantamab Sales Growth
4.5 Europe Elrantamab Sales Growth
4.6 Middle East & Africa Elrantamab Sales Growth
5 AMERICAS
5.1 Americas Elrantamab Sales by Country
5.1.1 Americas Elrantamab Sales by Country (2021-2026)
5.1.2 Americas Elrantamab Revenue by Country (2021-2026)
5.2 Americas Elrantamab Sales by Type (2021-2026)
5.3 Americas Elrantamab Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Elrantamab Sales by Region
6.1.1 APAC Elrantamab Sales by Region (2021-2026)
6.1.2 APAC Elrantamab Revenue by Region (2021-2026)
6.2 APAC Elrantamab Sales by Type (2021-2026)
6.3 APAC Elrantamab Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Elrantamab by Country
7.1.1 Europe Elrantamab Sales by Country (2021-2026)
7.1.2 Europe Elrantamab Revenue by Country (2021-2026)
7.2 Europe Elrantamab Sales by Type (2021-2026)
7.3 Europe Elrantamab Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Elrantamab by Country
8.1.1 Middle East & Africa Elrantamab Sales by Country (2021-2026)
8.1.2 Middle East & Africa Elrantamab Revenue by Country (2021-2026)
8.2 Middle East & Africa Elrantamab Sales by Type (2021-2026)
8.3 Middle East & Africa Elrantamab Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Elrantamab
10.3 Manufacturing Process Analysis of Elrantamab
10.4 Industry Chain Structure of Elrantamab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Elrantamab Distributors
11.3 Elrantamab Customer
12 WORLD FORECAST REVIEW FOR ELRANTAMAB BY GEOGRAPHIC REGION
12.1 Global Elrantamab Market Size Forecast by Region
12.1.1 Global Elrantamab Forecast by Region (2027-2032)
12.1.2 Global Elrantamab Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Elrantamab Forecast by Type (2027-2032)
12.7 Global Elrantamab Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Elrantamab Product Portfolios and Specifications
13.1.3 Pfizer Elrantamab Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Elrantamab Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Elrantamab by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Elrantamab by Country/Region, 2021, 2025 & 2032
2.2 Elrantamab Segment by Type
2.2.1 44 mg / 1.1 mL
2.2.2 76 mg / 1.9 mL
2.2.3 Elrantamab Sales by Type
2.2.3.1 Global Elrantamab Sales Market Share by Type (2021-2026)
2.2.3.2 Global Elrantamab Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Elrantamab Sale Price by Type (2021-2026)
2.3 Elrantamab Segment by Dosage Form
2.3.1 Subcutaneous Injection Solution
2.3.2 Lyophilized Powder for Injection
2.3.3 Elrantamab Sales by Dosage Form
2.3.3.1 Global Elrantamab Sales Market Share by Dosage Form (2021-2026)
2.3.3.2 Global Elrantamab Revenue and Market Share by Dosage Form (2021-2026)
2.3.3.3 Global Elrantamab Sale Price by Dosage Form (2021-2026)
2.4 Elrantamab Segment by Sales Channels
2.4.1 Hospital
2.4.2 Retail
2.4.3 Online
2.4.4 Elrantamab Sales by Sales Channels
2.4.4.1 Global Elrantamab Sales Market Share by Sales Channels (2021-2026)
2.4.4.2 Global Elrantamab Revenue and Market Share by Sales Channels (2021-2026)
2.4.4.3 Global Elrantamab Sale Price by Sales Channels (2021-2026)
2.5 Elrantamab Segment by Antibody Type
2.5.1 Monoclonal Antibody
2.5.2 Polyclonal Antibody
2.5.3 Bispecific Antibody
2.5.4 Elrantamab Sales by Antibody Type
2.5.4.1 Global Elrantamab Sales Market Share by Antibody Type (2021-2026)
2.5.4.2 Global Elrantamab Revenue and Market Share by Antibody Type (2021-2026)
2.5.4.3 Global Elrantamab Sale Price by Antibody Type (2021-2026)
2.6 Elrantamab Segment by Application
2.6.1 Monotherapy for Relapsed or Refractory Multiple Myeloma
2.6.2 Combination Therapy with Immunomodulators and Proteasome Inhibitors
2.6.3 Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
2.6.4 Otherts
2.6.5 Elrantamab Sales by Application
2.6.5.1 Global Elrantamab Sale Market Share by Application (2021-2026)
2.6.5.2 Global Elrantamab Revenue and Market Share by Application (2021-2026)
2.6.5.3 Global Elrantamab Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Elrantamab Breakdown Data by Company
3.1.1 Global Elrantamab Annual Sales by Company (2021-2026)
3.1.2 Global Elrantamab Sales Market Share by Company (2021-2026)
3.2 Global Elrantamab Annual Revenue by Company (2021-2026)
3.2.1 Global Elrantamab Revenue by Company (2021-2026)
3.2.2 Global Elrantamab Revenue Market Share by Company (2021-2026)
3.3 Global Elrantamab Sale Price by Company
3.4 Key Manufacturers Elrantamab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Elrantamab Product Location Distribution
3.4.2 Players Elrantamab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ELRANTAMAB BY GEOGRAPHIC REGION
4.1 World Historic Elrantamab Market Size by Geographic Region (2021-2026)
4.1.1 Global Elrantamab Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Elrantamab Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Elrantamab Market Size by Country/Region (2021-2026)
4.2.1 Global Elrantamab Annual Sales by Country/Region (2021-2026)
4.2.2 Global Elrantamab Annual Revenue by Country/Region (2021-2026)
4.3 Americas Elrantamab Sales Growth
4.4 APAC Elrantamab Sales Growth
4.5 Europe Elrantamab Sales Growth
4.6 Middle East & Africa Elrantamab Sales Growth
5 AMERICAS
5.1 Americas Elrantamab Sales by Country
5.1.1 Americas Elrantamab Sales by Country (2021-2026)
5.1.2 Americas Elrantamab Revenue by Country (2021-2026)
5.2 Americas Elrantamab Sales by Type (2021-2026)
5.3 Americas Elrantamab Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Elrantamab Sales by Region
6.1.1 APAC Elrantamab Sales by Region (2021-2026)
6.1.2 APAC Elrantamab Revenue by Region (2021-2026)
6.2 APAC Elrantamab Sales by Type (2021-2026)
6.3 APAC Elrantamab Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Elrantamab by Country
7.1.1 Europe Elrantamab Sales by Country (2021-2026)
7.1.2 Europe Elrantamab Revenue by Country (2021-2026)
7.2 Europe Elrantamab Sales by Type (2021-2026)
7.3 Europe Elrantamab Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Elrantamab by Country
8.1.1 Middle East & Africa Elrantamab Sales by Country (2021-2026)
8.1.2 Middle East & Africa Elrantamab Revenue by Country (2021-2026)
8.2 Middle East & Africa Elrantamab Sales by Type (2021-2026)
8.3 Middle East & Africa Elrantamab Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Elrantamab
10.3 Manufacturing Process Analysis of Elrantamab
10.4 Industry Chain Structure of Elrantamab
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Elrantamab Distributors
11.3 Elrantamab Customer
12 WORLD FORECAST REVIEW FOR ELRANTAMAB BY GEOGRAPHIC REGION
12.1 Global Elrantamab Market Size Forecast by Region
12.1.1 Global Elrantamab Forecast by Region (2027-2032)
12.1.2 Global Elrantamab Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Elrantamab Forecast by Type (2027-2032)
12.7 Global Elrantamab Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Elrantamab Product Portfolios and Specifications
13.1.3 Pfizer Elrantamab Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Elrantamab Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Elrantamab Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 44 mg / 1.1 mL
Table 4. Major Players of 76 mg / 1.9 mL
Table 5. Global Elrantamab Sales by Type (2021-2026) & (Units)
Table 6. Global Elrantamab Sales Market Share by Type (2021-2026)
Table 7. Global Elrantamab Revenue by Type (2021-2026) & ($ million)
Table 8. Global Elrantamab Revenue Market Share by Type (2021-2026)
Table 9. Global Elrantamab Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Subcutaneous Injection Solution
Table 11. Major Players of Lyophilized Powder for Injection
Table 12. Global Elrantamab Sales by Dosage Form (2021-2026) & (Units)
Table 13. Global Elrantamab Sales Market Share by Dosage Form (2021-2026)
Table 14. Global Elrantamab Revenue by Dosage Form (2021-2026) & ($ million)
Table 15. Global Elrantamab Revenue Market Share by Dosage Form (2021-2026)
Table 16. Global Elrantamab Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 17. Major Players of Hospital
Table 18. Major Players of Retail
Table 19. Major Players of Online
Table 20. Global Elrantamab Sales by Sales Channels (2021-2026) & (Units)
Table 21. Global Elrantamab Sales Market Share by Sales Channels (2021-2026)
Table 22. Global Elrantamab Revenue by Sales Channels (2021-2026) & ($ million)
Table 23. Global Elrantamab Revenue Market Share by Sales Channels (2021-2026)
Table 24. Global Elrantamab Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 25. Major Players of Monoclonal Antibody
Table 26. Major Players of Polyclonal Antibody
Table 27. Major Players of Bispecific Antibody
Table 28. Global Elrantamab Sales by Antibody Type (2021-2026) & (Units)
Table 29. Global Elrantamab Sales Market Share by Antibody Type (2021-2026)
Table 30. Global Elrantamab Revenue by Antibody Type (2021-2026) & ($ million)
Table 31. Global Elrantamab Revenue Market Share by Antibody Type (2021-2026)
Table 32. Global Elrantamab Sale Price by Antibody Type (2021-2026) & (US$/Unit)
Table 33. Global Elrantamab Sale by Application (2021-2026) & (Units)
Table 34. Global Elrantamab Sale Market Share by Application (2021-2026)
Table 35. Global Elrantamab Revenue by Application (2021-2026) & ($ million)
Table 36. Global Elrantamab Revenue Market Share by Application (2021-2026)
Table 37. Global Elrantamab Sale Price by Application (2021-2026) & (US$/Unit)
Table 38. Global Elrantamab Sales by Company (2021-2026) & (Units)
Table 39. Global Elrantamab Sales Market Share by Company (2021-2026)
Table 40. Global Elrantamab Revenue by Company (2021-2026) & ($ millions)
Table 41. Global Elrantamab Revenue Market Share by Company (2021-2026)
Table 42. Global Elrantamab Sale Price by Company (2021-2026) & (US$/Unit)
Table 43. Key Manufacturers Elrantamab Producing Area Distribution and Sales Area
Table 44. Players Elrantamab Products Offered
Table 45. Elrantamab Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 46. New Products and Potential Entrants
Table 47. Market M&A Activity & Strategy
Table 48. Global Elrantamab Sales by Geographic Region (2021-2026) & (Units)
Table 49. Global Elrantamab Sales Market Share Geographic Region (2021-2026)
Table 50. Global Elrantamab Revenue by Geographic Region (2021-2026) & ($ millions)
Table 51. Global Elrantamab Revenue Market Share by Geographic Region (2021-2026)
Table 52. Global Elrantamab Sales by Country/Region (2021-2026) & (Units)
Table 53. Global Elrantamab Sales Market Share by Country/Region (2021-2026)
Table 54. Global Elrantamab Revenue by Country/Region (2021-2026) & ($ millions)
Table 55. Global Elrantamab Revenue Market Share by Country/Region (2021-2026)
Table 56. Americas Elrantamab Sales by Country (2021-2026) & (Units)
Table 57. Americas Elrantamab Sales Market Share by Country (2021-2026)
Table 58. Americas Elrantamab Revenue by Country (2021-2026) & ($ millions)
Table 59. Americas Elrantamab Sales by Type (2021-2026) & (Units)
Table 60. Americas Elrantamab Sales by Application (2021-2026) & (Units)
Table 61. APAC Elrantamab Sales by Region (2021-2026) & (Units)
Table 62. APAC Elrantamab Sales Market Share by Region (2021-2026)
Table 63. APAC Elrantamab Revenue by Region (2021-2026) & ($ millions)
Table 64. APAC Elrantamab Sales by Type (2021-2026) & (Units)
Table 65. APAC Elrantamab Sales by Application (2021-2026) & (Units)
Table 66. Europe Elrantamab Sales by Country (2021-2026) & (Units)
Table 67. Europe Elrantamab Revenue by Country (2021-2026) & ($ millions)
Table 68. Europe Elrantamab Sales by Type (2021-2026) & (Units)
Table 69. Europe Elrantamab Sales by Application (2021-2026) & (Units)
Table 70. Middle East & Africa Elrantamab Sales by Country (2021-2026) & (Units)
Table 71. Middle East & Africa Elrantamab Revenue Market Share by Country (2021-2026)
Table 72. Middle East & Africa Elrantamab Sales by Type (2021-2026) & (Units)
Table 73. Middle East & Africa Elrantamab Sales by Application (2021-2026) & (Units)
Table 74. Key Market Drivers & Growth Opportunities of Elrantamab
Table 75. Key Market Challenges & Risks of Elrantamab
Table 76. Key Industry Trends of Elrantamab
Table 77. Elrantamab Raw Material
Table 78. Key Suppliers of Raw Materials
Table 79. Elrantamab Distributors List
Table 80. Elrantamab Customer List
Table 81. Global Elrantamab Sales Forecast by Region (2027-2032) & (Units)
Table 82. Global Elrantamab Revenue Forecast by Region (2027-2032) & ($ millions)
Table 83. Americas Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 84. Americas Elrantamab Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. APAC Elrantamab Sales Forecast by Region (2027-2032) & (Units)
Table 86. APAC Elrantamab Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 87. Europe Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 88. Europe Elrantamab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Middle East & Africa Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 90. Middle East & Africa Elrantamab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 91. Global Elrantamab Sales Forecast by Type (2027-2032) & (Units)
Table 92. Global Elrantamab Revenue Forecast by Type (2027-2032) & ($ millions)
Table 93. Global Elrantamab Sales Forecast by Application (2027-2032) & (Units)
Table 94. Global Elrantamab Revenue Forecast by Application (2027-2032) & ($ millions)
Table 95. Pfizer Basic Information, Elrantamab Manufacturing Base, Sales Area and Its Competitors
Table 96. Pfizer Elrantamab Product Portfolios and Specifications
Table 97. Pfizer Elrantamab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Pfizer Main Business
Table 99. Pfizer Latest Developments
Table 1. Elrantamab Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Elrantamab Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 44 mg / 1.1 mL
Table 4. Major Players of 76 mg / 1.9 mL
Table 5. Global Elrantamab Sales by Type (2021-2026) & (Units)
Table 6. Global Elrantamab Sales Market Share by Type (2021-2026)
Table 7. Global Elrantamab Revenue by Type (2021-2026) & ($ million)
Table 8. Global Elrantamab Revenue Market Share by Type (2021-2026)
Table 9. Global Elrantamab Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Subcutaneous Injection Solution
Table 11. Major Players of Lyophilized Powder for Injection
Table 12. Global Elrantamab Sales by Dosage Form (2021-2026) & (Units)
Table 13. Global Elrantamab Sales Market Share by Dosage Form (2021-2026)
Table 14. Global Elrantamab Revenue by Dosage Form (2021-2026) & ($ million)
Table 15. Global Elrantamab Revenue Market Share by Dosage Form (2021-2026)
Table 16. Global Elrantamab Sale Price by Dosage Form (2021-2026) & (US$/Unit)
Table 17. Major Players of Hospital
Table 18. Major Players of Retail
Table 19. Major Players of Online
Table 20. Global Elrantamab Sales by Sales Channels (2021-2026) & (Units)
Table 21. Global Elrantamab Sales Market Share by Sales Channels (2021-2026)
Table 22. Global Elrantamab Revenue by Sales Channels (2021-2026) & ($ million)
Table 23. Global Elrantamab Revenue Market Share by Sales Channels (2021-2026)
Table 24. Global Elrantamab Sale Price by Sales Channels (2021-2026) & (US$/Unit)
Table 25. Major Players of Monoclonal Antibody
Table 26. Major Players of Polyclonal Antibody
Table 27. Major Players of Bispecific Antibody
Table 28. Global Elrantamab Sales by Antibody Type (2021-2026) & (Units)
Table 29. Global Elrantamab Sales Market Share by Antibody Type (2021-2026)
Table 30. Global Elrantamab Revenue by Antibody Type (2021-2026) & ($ million)
Table 31. Global Elrantamab Revenue Market Share by Antibody Type (2021-2026)
Table 32. Global Elrantamab Sale Price by Antibody Type (2021-2026) & (US$/Unit)
Table 33. Global Elrantamab Sale by Application (2021-2026) & (Units)
Table 34. Global Elrantamab Sale Market Share by Application (2021-2026)
Table 35. Global Elrantamab Revenue by Application (2021-2026) & ($ million)
Table 36. Global Elrantamab Revenue Market Share by Application (2021-2026)
Table 37. Global Elrantamab Sale Price by Application (2021-2026) & (US$/Unit)
Table 38. Global Elrantamab Sales by Company (2021-2026) & (Units)
Table 39. Global Elrantamab Sales Market Share by Company (2021-2026)
Table 40. Global Elrantamab Revenue by Company (2021-2026) & ($ millions)
Table 41. Global Elrantamab Revenue Market Share by Company (2021-2026)
Table 42. Global Elrantamab Sale Price by Company (2021-2026) & (US$/Unit)
Table 43. Key Manufacturers Elrantamab Producing Area Distribution and Sales Area
Table 44. Players Elrantamab Products Offered
Table 45. Elrantamab Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 46. New Products and Potential Entrants
Table 47. Market M&A Activity & Strategy
Table 48. Global Elrantamab Sales by Geographic Region (2021-2026) & (Units)
Table 49. Global Elrantamab Sales Market Share Geographic Region (2021-2026)
Table 50. Global Elrantamab Revenue by Geographic Region (2021-2026) & ($ millions)
Table 51. Global Elrantamab Revenue Market Share by Geographic Region (2021-2026)
Table 52. Global Elrantamab Sales by Country/Region (2021-2026) & (Units)
Table 53. Global Elrantamab Sales Market Share by Country/Region (2021-2026)
Table 54. Global Elrantamab Revenue by Country/Region (2021-2026) & ($ millions)
Table 55. Global Elrantamab Revenue Market Share by Country/Region (2021-2026)
Table 56. Americas Elrantamab Sales by Country (2021-2026) & (Units)
Table 57. Americas Elrantamab Sales Market Share by Country (2021-2026)
Table 58. Americas Elrantamab Revenue by Country (2021-2026) & ($ millions)
Table 59. Americas Elrantamab Sales by Type (2021-2026) & (Units)
Table 60. Americas Elrantamab Sales by Application (2021-2026) & (Units)
Table 61. APAC Elrantamab Sales by Region (2021-2026) & (Units)
Table 62. APAC Elrantamab Sales Market Share by Region (2021-2026)
Table 63. APAC Elrantamab Revenue by Region (2021-2026) & ($ millions)
Table 64. APAC Elrantamab Sales by Type (2021-2026) & (Units)
Table 65. APAC Elrantamab Sales by Application (2021-2026) & (Units)
Table 66. Europe Elrantamab Sales by Country (2021-2026) & (Units)
Table 67. Europe Elrantamab Revenue by Country (2021-2026) & ($ millions)
Table 68. Europe Elrantamab Sales by Type (2021-2026) & (Units)
Table 69. Europe Elrantamab Sales by Application (2021-2026) & (Units)
Table 70. Middle East & Africa Elrantamab Sales by Country (2021-2026) & (Units)
Table 71. Middle East & Africa Elrantamab Revenue Market Share by Country (2021-2026)
Table 72. Middle East & Africa Elrantamab Sales by Type (2021-2026) & (Units)
Table 73. Middle East & Africa Elrantamab Sales by Application (2021-2026) & (Units)
Table 74. Key Market Drivers & Growth Opportunities of Elrantamab
Table 75. Key Market Challenges & Risks of Elrantamab
Table 76. Key Industry Trends of Elrantamab
Table 77. Elrantamab Raw Material
Table 78. Key Suppliers of Raw Materials
Table 79. Elrantamab Distributors List
Table 80. Elrantamab Customer List
Table 81. Global Elrantamab Sales Forecast by Region (2027-2032) & (Units)
Table 82. Global Elrantamab Revenue Forecast by Region (2027-2032) & ($ millions)
Table 83. Americas Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 84. Americas Elrantamab Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. APAC Elrantamab Sales Forecast by Region (2027-2032) & (Units)
Table 86. APAC Elrantamab Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 87. Europe Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 88. Europe Elrantamab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Middle East & Africa Elrantamab Sales Forecast by Country (2027-2032) & (Units)
Table 90. Middle East & Africa Elrantamab Revenue Forecast by Country (2027-2032) & ($ millions)
Table 91. Global Elrantamab Sales Forecast by Type (2027-2032) & (Units)
Table 92. Global Elrantamab Revenue Forecast by Type (2027-2032) & ($ millions)
Table 93. Global Elrantamab Sales Forecast by Application (2027-2032) & (Units)
Table 94. Global Elrantamab Revenue Forecast by Application (2027-2032) & ($ millions)
Table 95. Pfizer Basic Information, Elrantamab Manufacturing Base, Sales Area and Its Competitors
Table 96. Pfizer Elrantamab Product Portfolios and Specifications
Table 97. Pfizer Elrantamab Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Pfizer Main Business
Table 99. Pfizer Latest Developments
LIST OF FIGURES
Figure 1. Picture of Elrantamab
Figure 2. Elrantamab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Elrantamab Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Elrantamab Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Elrantamab Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Elrantamab Sales Market Share by Country/Region (2025)
Figure 10. Elrantamab Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 44 mg / 1.1 mL
Figure 12. Product Picture of 76 mg / 1.9 mL
Figure 13. Global Elrantamab Sales Market Share by Type in 2026
Figure 14. Global Elrantamab Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Subcutaneous Injection Solution
Figure 16. Product Picture of Lyophilized Powder for Injection
Figure 17. Global Elrantamab Sales Market Share by Dosage Form in 2026
Figure 18. Global Elrantamab Revenue Market Share by Dosage Form (2021-2026)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Retail
Figure 21. Product Picture of Online
Figure 22. Global Elrantamab Sales Market Share by Sales Channels in 2026
Figure 23. Global Elrantamab Revenue Market Share by Sales Channels (2021-2026)
Figure 24. Product Picture of Monoclonal Antibody
Figure 25. Product Picture of Polyclonal Antibody
Figure 26. Product Picture of Bispecific Antibody
Figure 27. Global Elrantamab Sales Market Share by Antibody Type in 2026
Figure 28. Global Elrantamab Revenue Market Share by Antibody Type (2021-2026)
Figure 29. Elrantamab Consumed in Monotherapy for Relapsed or Refractory Multiple Myeloma
Figure 30. Global Elrantamab Market: Monotherapy for Relapsed or Refractory Multiple Myeloma (2021-2026) & (Units)
Figure 31. Elrantamab Consumed in Combination Therapy with Immunomodulators and Proteasome Inhibitors
Figure 32. Global Elrantamab Market: Combination Therapy with Immunomodulators and Proteasome Inhibitors (2021-2026) & (Units)
Figure 33. Elrantamab Consumed in Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
Figure 34. Global Elrantamab Market: Exploration in First-Line or Second-Line Treatment of Multiple Myeloma (2021-2026) & (Units)
Figure 35. Elrantamab Consumed in Otherts
Figure 36. Global Elrantamab Market: Otherts (2021-2026) & (Units)
Figure 37. Global Elrantamab Sale Market Share by Application (2025)
Figure 38. Global Elrantamab Revenue Market Share by Application in 2025
Figure 39. Elrantamab Sales by Company in 2025 (Units)
Figure 40. Global Elrantamab Sales Market Share by Company in 2025
Figure 41. Elrantamab Revenue by Company in 2025 ($ millions)
Figure 42. Global Elrantamab Revenue Market Share by Company in 2025
Figure 43. Global Elrantamab Sales Market Share by Geographic Region (2021-2026)
Figure 44. Global Elrantamab Revenue Market Share by Geographic Region in 2025
Figure 45. Americas Elrantamab Sales 2021-2026 (Units)
Figure 46. Americas Elrantamab Revenue 2021-2026 ($ millions)
Figure 47. APAC Elrantamab Sales 2021-2026 (Units)
Figure 48. APAC Elrantamab Revenue 2021-2026 ($ millions)
Figure 49. Europe Elrantamab Sales 2021-2026 (Units)
Figure 50. Europe Elrantamab Revenue 2021-2026 ($ millions)
Figure 51. Middle East & Africa Elrantamab Sales 2021-2026 (Units)
Figure 52. Middle East & Africa Elrantamab Revenue 2021-2026 ($ millions)
Figure 53. Americas Elrantamab Sales Market Share by Country in 2025
Figure 54. Americas Elrantamab Revenue Market Share by Country (2021-2026)
Figure 55. Americas Elrantamab Sales Market Share by Type (2021-2026)
Figure 56. Americas Elrantamab Sales Market Share by Application (2021-2026)
Figure 57. United States Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 58. Canada Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 59. Mexico Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 60. Brazil Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 61. APAC Elrantamab Sales Market Share by Region in 2025
Figure 62. APAC Elrantamab Revenue Market Share by Region (2021-2026)
Figure 63. APAC Elrantamab Sales Market Share by Type (2021-2026)
Figure 64. APAC Elrantamab Sales Market Share by Application (2021-2026)
Figure 65. China Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 66. Japan Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 67. South Korea Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 68. Southeast Asia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 69. India Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 70. Australia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 71. China Taiwan Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 72. Europe Elrantamab Sales Market Share by Country in 2025
Figure 73. Europe Elrantamab Revenue Market Share by Country (2021-2026)
Figure 74. Europe Elrantamab Sales Market Share by Type (2021-2026)
Figure 75. Europe Elrantamab Sales Market Share by Application (2021-2026)
Figure 76. Germany Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 77. France Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 78. UK Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 79. Italy Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 80. Russia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 81. Middle East & Africa Elrantamab Sales Market Share by Country (2021-2026)
Figure 82. Middle East & Africa Elrantamab Sales Market Share by Type (2021-2026)
Figure 83. Middle East & Africa Elrantamab Sales Market Share by Application (2021-2026)
Figure 84. Egypt Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 85. South Africa Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 86. Israel Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 87. Turkey Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 88. GCC Countries Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 89. Manufacturing Cost Structure Analysis of Elrantamab in 2026
Figure 90. Manufacturing Process Analysis of Elrantamab
Figure 91. Industry Chain Structure of Elrantamab
Figure 92. Channels of Distribution
Figure 93. Global Elrantamab Sales Market Forecast by Region (2027-2032)
Figure 94. Global Elrantamab Revenue Market Share Forecast by Region (2027-2032)
Figure 95. Global Elrantamab Sales Market Share Forecast by Type (2027-2032)
Figure 96. Global Elrantamab Revenue Market Share Forecast by Type (2027-2032)
Figure 97. Global Elrantamab Sales Market Share Forecast by Application (2027-2032)
Figure 98. Global Elrantamab Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Elrantamab
Figure 2. Elrantamab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Elrantamab Sales Growth Rate 2021-2032 (Units)
Figure 7. Global Elrantamab Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Elrantamab Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Elrantamab Sales Market Share by Country/Region (2025)
Figure 10. Elrantamab Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 44 mg / 1.1 mL
Figure 12. Product Picture of 76 mg / 1.9 mL
Figure 13. Global Elrantamab Sales Market Share by Type in 2026
Figure 14. Global Elrantamab Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Subcutaneous Injection Solution
Figure 16. Product Picture of Lyophilized Powder for Injection
Figure 17. Global Elrantamab Sales Market Share by Dosage Form in 2026
Figure 18. Global Elrantamab Revenue Market Share by Dosage Form (2021-2026)
Figure 19. Product Picture of Hospital
Figure 20. Product Picture of Retail
Figure 21. Product Picture of Online
Figure 22. Global Elrantamab Sales Market Share by Sales Channels in 2026
Figure 23. Global Elrantamab Revenue Market Share by Sales Channels (2021-2026)
Figure 24. Product Picture of Monoclonal Antibody
Figure 25. Product Picture of Polyclonal Antibody
Figure 26. Product Picture of Bispecific Antibody
Figure 27. Global Elrantamab Sales Market Share by Antibody Type in 2026
Figure 28. Global Elrantamab Revenue Market Share by Antibody Type (2021-2026)
Figure 29. Elrantamab Consumed in Monotherapy for Relapsed or Refractory Multiple Myeloma
Figure 30. Global Elrantamab Market: Monotherapy for Relapsed or Refractory Multiple Myeloma (2021-2026) & (Units)
Figure 31. Elrantamab Consumed in Combination Therapy with Immunomodulators and Proteasome Inhibitors
Figure 32. Global Elrantamab Market: Combination Therapy with Immunomodulators and Proteasome Inhibitors (2021-2026) & (Units)
Figure 33. Elrantamab Consumed in Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
Figure 34. Global Elrantamab Market: Exploration in First-Line or Second-Line Treatment of Multiple Myeloma (2021-2026) & (Units)
Figure 35. Elrantamab Consumed in Otherts
Figure 36. Global Elrantamab Market: Otherts (2021-2026) & (Units)
Figure 37. Global Elrantamab Sale Market Share by Application (2025)
Figure 38. Global Elrantamab Revenue Market Share by Application in 2025
Figure 39. Elrantamab Sales by Company in 2025 (Units)
Figure 40. Global Elrantamab Sales Market Share by Company in 2025
Figure 41. Elrantamab Revenue by Company in 2025 ($ millions)
Figure 42. Global Elrantamab Revenue Market Share by Company in 2025
Figure 43. Global Elrantamab Sales Market Share by Geographic Region (2021-2026)
Figure 44. Global Elrantamab Revenue Market Share by Geographic Region in 2025
Figure 45. Americas Elrantamab Sales 2021-2026 (Units)
Figure 46. Americas Elrantamab Revenue 2021-2026 ($ millions)
Figure 47. APAC Elrantamab Sales 2021-2026 (Units)
Figure 48. APAC Elrantamab Revenue 2021-2026 ($ millions)
Figure 49. Europe Elrantamab Sales 2021-2026 (Units)
Figure 50. Europe Elrantamab Revenue 2021-2026 ($ millions)
Figure 51. Middle East & Africa Elrantamab Sales 2021-2026 (Units)
Figure 52. Middle East & Africa Elrantamab Revenue 2021-2026 ($ millions)
Figure 53. Americas Elrantamab Sales Market Share by Country in 2025
Figure 54. Americas Elrantamab Revenue Market Share by Country (2021-2026)
Figure 55. Americas Elrantamab Sales Market Share by Type (2021-2026)
Figure 56. Americas Elrantamab Sales Market Share by Application (2021-2026)
Figure 57. United States Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 58. Canada Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 59. Mexico Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 60. Brazil Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 61. APAC Elrantamab Sales Market Share by Region in 2025
Figure 62. APAC Elrantamab Revenue Market Share by Region (2021-2026)
Figure 63. APAC Elrantamab Sales Market Share by Type (2021-2026)
Figure 64. APAC Elrantamab Sales Market Share by Application (2021-2026)
Figure 65. China Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 66. Japan Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 67. South Korea Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 68. Southeast Asia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 69. India Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 70. Australia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 71. China Taiwan Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 72. Europe Elrantamab Sales Market Share by Country in 2025
Figure 73. Europe Elrantamab Revenue Market Share by Country (2021-2026)
Figure 74. Europe Elrantamab Sales Market Share by Type (2021-2026)
Figure 75. Europe Elrantamab Sales Market Share by Application (2021-2026)
Figure 76. Germany Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 77. France Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 78. UK Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 79. Italy Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 80. Russia Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 81. Middle East & Africa Elrantamab Sales Market Share by Country (2021-2026)
Figure 82. Middle East & Africa Elrantamab Sales Market Share by Type (2021-2026)
Figure 83. Middle East & Africa Elrantamab Sales Market Share by Application (2021-2026)
Figure 84. Egypt Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 85. South Africa Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 86. Israel Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 87. Turkey Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 88. GCC Countries Elrantamab Revenue Growth 2021-2026 ($ millions)
Figure 89. Manufacturing Cost Structure Analysis of Elrantamab in 2026
Figure 90. Manufacturing Process Analysis of Elrantamab
Figure 91. Industry Chain Structure of Elrantamab
Figure 92. Channels of Distribution
Figure 93. Global Elrantamab Sales Market Forecast by Region (2027-2032)
Figure 94. Global Elrantamab Revenue Market Share Forecast by Region (2027-2032)
Figure 95. Global Elrantamab Sales Market Share Forecast by Type (2027-2032)
Figure 96. Global Elrantamab Revenue Market Share Forecast by Type (2027-2032)
Figure 97. Global Elrantamab Sales Market Share Forecast by Application (2027-2032)
Figure 98. Global Elrantamab Revenue Market Share Forecast by Application (2027-2032)
